CD8A and neoplasm: Huang et al. demonstrated that a mitomycin C-pre-treated MCaP0008 cancer vaccine stimulated splenic CD8+ T cells to produce IFN-γ, but it did not inhibit tumour growth in mice bearing orthotopic MCaP0008 breast cancer, suggesting immune tolerance.